Author:
Zhang Siqin,Di Lingfang,Qi Yan,Qian Xiang,Wang Siwei
Abstract
Patients with severe carbapenem-resistant Acinetobacter baumannii (CRAB) infections currently face significant treatment challenges. When patients display signs of infection and the clinical suspicion of CRAB infections is high, appropriate treatment should be immediately provided. However, current treatment plans and clinical data for CRAB are limited. Inherent and acquired resistance mechanisms, as well as host factors, significantly restrict options for empirical medication. Moreover, inappropriate drug coverage can have detrimental effects on patients. Most existing studies have limitations, such as a restricted sample size, and are predominantly observational or non-randomized, which report significant variability in patient infection severity and comorbidities. Therefore, a gold-standard therapy remains lacking. Current and future treatment options of infections due to CRAB were described in this review. The dose and considerable side effects restrict treatment options for polymyxins, and high doses of ampicillin-sulbactam or tigecycline appear to be the best option at the time of initial treatment. Moreover, new drugs such as durlobactam and cefiderocol have substantial therapeutic capabilities and may be effective salvage treatments. Bacteriophages and antimicrobial peptides may serve as alternative treatment options in the near future. The advantages of a combination antimicrobial regimen appear to predominate those of a single regimen. Despite its significant nephrotoxicity, colistin is considered a primary treatment and is often used in combination with antimicrobials, such as tigecycline, ampicillin-sulbactam, meropenem, or fosfomycin. The Infectious Diseases Society of America (IDSA) has deemed high-dose ampicillin-sulbactam, which is typically combined with high-dose tigecycline, polymyxin, and other antibacterial agents, the best option for treating serious CRAB infections. A rational combination of drug use and the exploration of new therapeutic drugs can alleviate or prevent the effects of CRAB infections, shorten hospital stays, and reduce patient mortality.
Funder
Medical Science and Technology Project of Zhejiang Province
Reference113 articles.
1. Contemporary perspective on the treatment of acinetobacter baumannii infections: insights from the society of infectious diseases pharmacists;Abdul-Mutakabbir;Infect. Dis. Ther.,2021
2. Efficacy of loading dose of colistin in Acinetobacter baumannii ventilator-associated pneumonia;Alp;Infez. Med.,2017
3. Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii;Al-Shaer;Ann. Pharmacother.,2014
4. Acinetobacter baumanniiEfficacy of fosfomycin-containing regimens for treatment of bacteremia due to pan-drug resistant in critically ill patients: A case series study;Assimakopoulos;Pathogens,2023
5. Triple combination therapy with high-dose ampicillin/sulbactam, high-dose tigecycline and colistin in the treatment of ventilator-associated pneumonia caused by pan-drug resistant Acinetobacter baumannii: a case series study;Assimakopoulos;Infez. Med.,2019